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ABSTRACT
Objective: To evaluate the relevance of the blood B-cell
subset profile for the diagnosis of Sjo ¨gren syndrome.
Methods: The distribution of mature blood B cells from
Bm1 through Bm5 was determined in 161 patients, of
whom 25 fulfilled the American–European Consensus
Group criteria for primary SS (pSS), and 136 served as
disease controls.
Results: The percentage of Bm2 and Bm29 cells was
increased in the patients with pSS compared with 54
patients with rheumatoid arthritis (RA) and 18 with
systemic lupus erythematosus (SLE) (p,0.001 for the
two comparisons). In contrast, those of early Bm5 (eBm5)
and Bm5 were decreased in patients with pSS, compared
with patients with RA and with SLE (p,0.001 for the two
comparisons). The receiver operating characteristic
curves allowed for an optimising cut-off value of
Bm2+Bm29 cells at 71.1% for 88.0% sensitivity and
83.1% specificity, that of eBm5+Bm5 cells at (13.5% for
84.0% sensitivity and 83.1% specificity, and, conse-
quently, that of Bm2+Bm29/eBm5+Bm5 at >5 for 88.0%
sensitivity and 84.6% specificity.
Conclusion: Given its presentation as a signature for
pSS, relative to RA and SLE, such a distribution of B-cell
subsets might provide a useful diagnostic tool.
Autoimmune exocrinopathy
1 is referred to as
Sjo ¨gren syndrome (SS). This occurs alone as
primary SS (pSS), or against a background of
connective tissue disease as secondary SS (sSS).
Even though keratoconjunctivitis sicca (resulting
from the involvement of lachrymal glands) and
xerostomia (resulting from the involvement of
salivary glands) are usually prominent, SS presents
as a multifaceted condition with a broad variety of
clinical manifestations and biological abnormal-
ities.
This polymorphism accounts for the delay in the
diagnosis, associated with underestimation of the
patients’ concerns made by the doctor, which
consequently discourages patients from taking
medical advice as symptoms arise. As a conse-
quence, there is every likelihood that the preva-
lence of the disease is far higher than previously
estimated.
2
These disadvantages are being over-ridden by the
emergence of new and potentially active treat-
ments, most notably anti-B lymphocyte antibodies
(Abs). In the setting of autoimmune diseases, the
latter have proved effective in rheumatoid arthritis
(RA) and systemic lupus erythematosus (SLE), and
are currently being tested in pSS.
34Thus, the need
for an early diagnosis of pSS has become a priority.
To this end, criteria for classification of the disease
have been defined
5 by the European Community
Study Group on diagnostic criteria for SS, and
amended
6 by the American–European Consensus
Group (AECG). At this time, special emphasis has
been placed on laboratory tests.
Concomitant evidence has sparked a great deal
of interest in the possibility that B cells play a
leading role in the pathogenesis of pSS.
7–10 Among
major breakthroughs in this interpretation is the
dissection of B-lymphocyte subsets. In particular,
the respective membrane expression of IgD and
CD38 distributes mature B cells (Bm) into sequen-
tial stages from Bm1 through Bm5 cells.
11 Once
activated in secondary lymphoid organs, naı ¨ve Bm1
(IgD+/CD382) become Bm2 (IgD+, CD38+), and
progress to germinal centre founder Bm29 cells
(IgD+/CD38++). There, they evolve into Bm3
centroblasts and Bm4 centrocytes (IgD2/CD38+),
which differentiate into either plasma cells, or early
(eBm5) and late memory Bm5 (IgD2/CD38+ and
IgD2/CD382, respectively). Inside the germinal
centres, a few cells of each subset escape into the
circulation. For unknown reasons, patients with
pSS exhibit disturbed B-cell subset distribution in
their blood,
12–14 and accumulate memory B cells
within their exocrine glands.
12 13 15
Our aim was to verify whether these distur-
bances are sufficiently characteristic to provide an
additional criterion to those selected
6 by the AECG.
There appeared to be a high ratio of increased
percentages of blood Bm2-plus-Bm29 cells to
decreased percentages of eBm5-plus-Bm5 cells that
differentiates pSS from RA, SLE and other mis-
cellaneous diseases.
PATIENTS AND METHODS
Patients with Sjo ¨gren syndrome, disease and
normal controls
Details of 177 patients who underwent blood
Bm1–Bm5 analysis from January 2002 onwards
were reviewed in June 2007. An aliquot was
retained for B-cell phenotyping at the time of
sampling for serological tests, in connection with
routine examination for connective tissue diseases
in the rheumatology ward at Brest Medical School
Hospital.
A double-blind approach was devised to analyse
Bm1–Bm5 distribution. B-cell subsets were studied
by the laboratory staff without knowledge of the
patients’ diagnosis, which was concurrently estab-
lished by the clinical staff without knowledge of
the Bm1–Bm5 distribution.
Twenty-five patients with an AECG-based
diagnosis of pSS,
6 54 with an American
Rheumatism Association-based diagnosis of RA,
16
and 18 with an American College of
Rheumatology-based diagnosis of SLE were
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17 Another 16 patients were classified as
undifferentiated arthritis, 11 as osteoarthritis, 8 as fibromyalgia,
7 as spondyloarthropathy, 5 as sicca symptoms of unknown
origin, 3 as polymyalgia, 3 as gouty arthritis, 3 as lupus
syndrome, and, 1 case each, as viral C hepatitis-associated sicca
symptoms, Lyme’s disease, reflex sympathetic dystrophy, low-
back pain, lumbar radiculopathy, arthritis-associated paraneo-
plastic syndrome, unexplained inflammatory syndrome and
autoimmune thrombocytopenia. Finally, 16 patients were
excluded from the first set of analyses, because SS was
secondary (n=8), lymphoma associated (n=2), or sufficient
clinical details unavailable (n=6).
Overall, there were three men and 22 women, mean (SD) age
57.2 (13.2) years, with pSS, and 25 men and 111 women, aged
54.2 (14.7) years, with allied autoimmune condition. Among
these disease controls, 12 men and 42 women aged 56.0 (12.3)
years had RA, and 18 women aged 44.3 (15.0) years had SLE. In
addition, 8 male and 18 female healthy volunteers, aged 36.8
(11.6) years, were the normal controls.
Flow cytometric analysis
Blood mononuclear cells were isolated by Ficoll–Hypaque
centrifugation and all Abs were purchased from Beckman-
Coulter (Hialeah, Florida, USA). Phycoerythrin-cyanin 7 (PC7)-
labelled anti-CD19 monoclonal Ab (J4;119) was used to tag B
cells, fluorescein isothiocyanate-labelled IgD (IA6-2) and PC5-
labelled CD38 (LS198) to count Bm1–Bm5 subsets.
13 The cells
were categorised on an Epics XL (Beckman-Coulter) fluores-
cence-activated cell-sorter (FACS).
Statistical analysis
Quantitative variables were expressed as means (SD). We first
used the Mann–Whitney U test to compare the distribution of
B-cell subsets in pSS, RA, SLE and NC groups. Then, each case
of pSS was classified according to the AECG criteria, and to the
B-cell subsets (table 1). The Cohen k indices were computed to
compare AECG-based diagnosis with B-cell subset-based diag-
nosis. Sensitivities and specificities were calculated for different
cut-off values for each B-cell subset levels. Receiver operating
characteristic curves were plotted to locate the value nearest the
northwest point of these curves which defines the best
combination of sensitivity and specificity. When two similar
values were obtained the best sensitivity was taken.
Calculations were made using the 2007 statistical package for
social sciences (SPSS, Chicago, Illinois, USA).
RESULTS
B-cell subsets in patients with pSS, RA and SLE, and in normal
controls
Distribution of blood B-cell subsets was determined in four
groups of subjects (table 2); fig 1 shows representative
examples. As described,
12 13 15 percentages of circulating
Bm2+Bm29 cells were higher in patients with pSS than in
normal controls (mean (SD) 77.7 (13.3)% vs 47.3 (4.5)%:
Table 1 Clinical features and B-cell subsets of 25 patients with primary Sjo ¨gren syndrome (pSS) according
the American–European Consensus Group (AECG)
Patients
with pSS
AECG items*
Immunosuppressive
drugs
Bm2+Bm29/
eBm5+Bm5 I II III IV V VI
1 ++2 ++ 2 MTX 15 mg/week 0.9
PDN 6 mg/day
2 +++ 22+ 2 1.6
3 ++ 2 + 2 + 2 4.3
4 ++ 2 + 2 + HCQ 400 mg/day 5.0
5 +++++ + 2 5.4
6 +++++ + 2 5.6
7 +++++ 22 6.0
8 ++++ 22 2 6.3
9 +++++ 2 HCQ 400 mg/day 7.6
10 +++++ + HCQ 400 mg/day 7.6
PDN 5 mg/day
11 + 2 +++ + 2 7.6
12 +++++ + 2 7.7
13 +++++ 22 7.8
14 +++++ + PDN 7 mg/day 8.4
15 +++ 2 ++2 9.1
16 +++ 22+ HCQ 400 mg/day 9.6
17 ++ 2 ++ + 2 9.6
18 ++ 2 + 2 + 2 12.6
19 +++ 2 ++2 13.7
20 ++ 2 + 2 + HCQ 400 mg/day 14.6
21 +++++ + HCQ 400 mg/day 16.0
22 +++++ + 2 16.3
23 +++++ + 2 18.8
24 2 ++++ + 2 29.6
25 +++++ + 2 35.2
*AECG items
6: I, ocular symptoms; II, oral symptoms; III, objective ocular signs (Schirmer’s test (5 mm in 5 min); IV, lip biopsy
with focus score >1; V, objective evidence of salivary gland involvement (unstimulated whole salivary flow (1.5 ml in 15 min);
VI, anti-SSA and/or anti-SSB. (+), item fulfilled; (2), item not fulfilled.
HCQ, hydroxychloroquine; MTX, methotrexate; PDN, prednisone.
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with RA (48.8 (17.5)%: p,0.001) and patients with SLE (56.5
(18.5)%: p,0.001). Therefore, the percentages of memory
eBm5+Bm5 were decreased in patients with pSS, relative to
normal controls (10.9 (7.2)% vs 28.5 (9.1)%: p,0.001), and to
patients with RA and SLE (10.9 (7.2)% vs 27.9 (12.0)% and 24.2
(12.7)%, respectively: p,0.001 for both comparisons).
Relevance of B-cell subset profile to the diagnosis of pSS
Relationships between AECG-based diagnosis of pSS and B-cell
subsets (taken alone or in combination) were evaluated in 25
patients with pSS and 136 disease controls. The best combina-
tions for the diagnosis of pSS (fig 2A, table 3) were Bm2+Bm29
>71.1% (sensitivity 88.0% and specificity 83.1%), eBm5+Bm5
(13.5% (sensitivity 84.0% and specificity 83.1%), and, even
better, the ratio of Bm2+Bm29 to eBm5+Bm5 >5 (sensitivity
88.0% and specificity 84.6%). Lower associations were seen
(fig 2B) with eBm5 (6.7% alone (sensitivity 80.0% and
specificity 72.8%), Bm5 (7.6% alone (sensitivity 84.0% and
specificity 80.1%), and Bm2 >59.9% alone (sensitivity 80.0%
and specificity 75.7%). Parenthetically, the relative percentages
of Bm1 and Bm29 were weakly associated with pSS.
Anti-sicca syndrome (SS)A and anti-SSB Abs were then tested
in these 161 subjects. Compared with Bm2+Bm29/eBm5+Bm5
>5, they had lower sensitivity (76.0% for anti-SSA and 28.0%
for anti-SSB vs 88.0% for the ratio of B-cell subsets), but a higher
specificity (97.1% for anti-SSA and 97.8% for anti-SSB vs 84.6%
for the ratio of B-cell subsets). Association of Bm2+Bm29/
eBm5+Bm5>5 with anti-SSA and/or anti-SSB raised the
specificity to 99.3%, but reduced the sensitivity to 68.0%.
Agreement between AECG criteria and Bm2+Bm29/eBm5+Bm5
>5
AECG-based criteria match the Bm2+Bm29/eBm5+Bm5 >5
patterns in 137/161 (85.1%) cases (95% confidence interval
78.4 to 90.0 for k=0.56). Of the 25 patients fulfilling the AECG
criteria for pSS, only three had Bm2+Bm29/eBm5+Bm5 ,5.
Twenty-one cases of Bm2+Bm29/eBm5+Bm5 .5 were
observed in the absence of pSS. These consisted of seven RA,
four SLE, three undifferentiated arthritis, two psoriatic arthritis,
two fibromyalgia, one sicca syndrome of unknown origin, one
gouty arthritis and one osteoarthritis.
Classification according to B-cell subset, serum and
histopathology criteria
The three criteria, Bm2+Bm29/eBm5+Bm5 >5, anti-SSA and/or
anti-SSB, and focus score >1, were ranked in a classification-tree
(fig3).Ofthe25patientswithpSS,22hadBm2+Bm29/eBm5+Bm5
>5, 21 a focus score >1 and 20 anti-SSA and/or anti-SSB.
Within the AECG criteria, the 25 patients displayed anti-SSA
and/or anti-SSB and/or a focus score >1.Conversely,among those
22 with Bm2+Bm29/eBm5+Bm5 >5, 15 had anti-SSA and/or anti-
SSB, plus a focus score >1. Three had anti-SSA and/or anti-SSB,
but not a focus score >1, while four had a focus score >1, but not
anti-SSA and/or anti-SSB. Of the remaining three patients with
Bm2+Bm29/eBm5+Bm5 ,5, only one had a focus score >1.
Circulating B-cell subsets in sSS, or sicca symptoms of unknown
origin
Five cases with RA, two with SLE and one with undifferentiated
arthritis were clinically classified as sSS. Of these, a first
subgroup of four had Bm2+Bm29/eBm5+Bm5 >5, of whom
three fulfilled the AECG criteria for SS. The fourth patient had a
focus score >1, but the results of her unstimulated salivary flow
were not available. A second subgroup of four patients with sSS
had Bm2+Bm29/eBm5+Bm5 ,5, of whom none met the AECG
criteria. That is, all the patients who fulfilled the AECG criteria
had Bm2+Bm29/eBm5+Bm5 >5. The B-cell subset distribution
patterns might thus be as specific for sSS as for pSS.
By definition, none of five patients with sicca symptoms of
unknown origin met the AECG criteria. The anti-SSA and/or
anti-SSB Ab tests and the focus score were negative, but one of
these five (not the patient with viral C hepatitis-associated sicca
symptoms) had Bm2+Bm29/eBm5+Bm5 >5.
Table 2 Blood B-cell subsets or subset combinations (means (SD) of percentage) in patients with primary
Sjo ¨gren syndrome (pSS), compared with patients with rheumatoid arthritis (RA) or systemic lupus
erythematosus (SLE), and with normal controls
B-cell subsets or combinations of
subsets
Disease controls
Normal controls
(n=26)
pSS
(n=25)
RA
(n=54)
SLE
(n=18)
Bm1* 9.9 (7.5) 20.2 (10.3) 15.2 (14.1) 21.2 (8.6)
p,0.001 NS p,0.001
Bm2 65.2 (11.5) 44.8 (15.3) 48.5 (14.7) 43.3 (12.1)
p,0.001 p,0.001 p,0.001
Bm29 12.5 (9.9) 4.0 (5.2) 8.0 (7.2) 4.0 (2.7)
p,0.001 NS p,0.001
Bm2+Bm29 77.7 (13.3) 48.8 (17.5) 56.5 (18.5) 47.3 (4.5)
p,0.001 p,0.001 p,0.001
early Bm5 (eBm5) 5.3 (3.2) 11.0 (4.7) 10.2 (4.9) 13.2 (4.5)
p,0.001 p,10
23 p,0.001
Bm5 5.6 (4.3) 16.9 (9.1) 14.0 (8.9) 15.3 (6.9)
p,0.001 p,0.001 p,0.001
eBm5+Bm5 10.9 (7.2) 27.9 (12.0) 24.2 (12.7) 28.5 (9.1)
p,0.001 p,0.001 p,0.001
Bm2+Bm29/eBm5+Bm5 10.7 (7.9) 2.5 (2.2) 3.4 (2.7) 2.0 (1.1)
p,0.001 p,0.001 p,0.001
All p values are in comparison with patients with pSS.
*Bm, mature B lymphocyte classified from Bm1 through Bm5, according to the relative membrane expression of IgD and CD38.
11
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The diagnosis of pSS remains problematic for rheumatologists
owing to the lack of specific tests, and therefore its largely
subjective approach. This is one of the reasons, not only why
the prevalence of the disease varies from one study to another
2
but also why the proposal of different sets of criteria is never
ending.
56 Nonetheless, AECG criteria have produced major
progresses in this area of research. The latest criteria were
indeed based on objective tests, and had forced the experts in
the field to reach agreement. Yet, the question is not settled,
since doubts can be cast on any item selected.
18 19
Although intended to optimise collaboration between the
groups,
20 these classification criteria are routinely treated as
diagnostic criteria. In practice, a patient’s sensitivity and
specificity have to be high to allow for an early diagnosis at
the beginning of the disease. Furthermore, their improvement is
desirable, and the diagnosis worthwhile, given that B-cell
depletion could prove a very efficient treatment in the early
stages of the disease, but less so in its advanced stages.
34
In pSS, there is an increase in the level of Bm2/Bm29 cells,
with a reciprocal decrease in that of eBm5/Bm5. The absence of
these two changes in RA and SLE assigns to the blood B-cell
subset profile some relevance to the diagnosis of pSS.
13 14 In
addition, our analysis establishes that the sensitivity and
specificity of just the ratio of Bm2+Bm29 to eBm5+Bm5 are as
good as the entire set of AECG criteria. The sensitivity is higher,
and the specificity lower, than anti-SSA and/or anti-SSB. This is
remarkable as anti-SSA and/or anti-SSB belong to the AECG
Figure 1 Expression of IgD and CD38 distributes mature B (Bm) cells into sequential subsets from Bm1 through Bm5.
11 These dot plots are
representative examples of fluorescence-activated cell-sorter analysis of patients with primary Sjo ¨gren syndrome (pSS), rheumatoid arthritis (RA), or
systemic lupus erythematosus (SLE), and of normal controls.
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the inclusion of some patients in this study.
The diagnostic weight of the B-cell subset profile would be
even better in a cohort survey than in our cross-sectional
analysis. Undoubtedly, the specificity of Bm2+Bm29/
eBm5+Bm5 >5 should be improved in this prospective study,
relative to our pilot study. That is, we may safely predict that
some cases were false positive, just because the results of a few
tests were not available. Actually, some of these patients should
have been confirmed as having pSS, and the diagnostic value of
Bm2+Bm29/eBm5+Bm5 improved accordingly. Clearly, this
problem warrants examination prospectively in patients with
early pSS.
The threat that hangs over patients with pSS is the
development of a lymphoma.
21 22 There are currently no
reported data relating the alterations in B-cell subsets with the
disease duration, inflammatory activity or risk of lymphoma
development in pSS. Unfortunately, we have thus far no
sufficient data to deal with such pertinent concerns.
Consequently, a new prospective study evaluating parotid
enlargement and/or palpable purpura and/or reduced levels of
C4
22 for each patient is currently being conducted. This is an
attempt to compare patients at ‘‘high risk’’ and patients at ‘‘low
risk’’ of lymphoma development relative to their B-cell subset
distribution.
B-cell subset disturbances appear to be a signature for SS. Our
finding that the Bm2+Bm29 to eBm5+Bm5 ratio does not reach
5 in SS is sufficient to set this syndrome apart from other
rheumatic autoimmune diseases, where a reduced ratio is
exceptional. Interestingly, after rituximab treatment, the
original abnormalities of B cells (increased Bm2, and decreased
memory B cells) are reproduced over time.
23 Another three
arguments supporting a case for this analysis are first, the FACS
analysis required to achieve this classification is simple to do,
second, the data can be quickly obtained and finally, the results
are reproducible. In a way, this simple test could be more readily
available to the community doctor than biopsy of the labial
minor salivary glands. Should not this be validated as a
Figure 2 Receiver-operating characteristic curves of B-cell subsets for
the diagnosis of primary Sjo ¨gren syndrome.
Table 3 Optimal levels of B-cell subsets for the diagnosis of primary
Sjo ¨gren syndrome (in decreasing order)
B-cell subsets Cut-off point (%) Sensitivity (%) Specificity (%)
Bm2+Bm29/eBm5+Bm5 >5.0 88.0 84.6
Bm2+Bm29> 71.1 88.0 83.1
eBm5+Bm5 (13.5 84.0 83.1
Bm5 (7.6 84.0 80.1
eBm5 (6.7 80.0 72.8
Bm2 >59.9 80.0 75.7
Bm29> 5.1 84.0 61.8
Bm1 (12.9 80.0 64.0
*Bm, mature B lymphocyte classified from Bm1 through Bm5, according to the
relative membrane expression of IgD and CD38.
11
Figure 3 Classification tree for primary Sjo ¨gren syndrome (pSS) according to serological, histopathological and phenotypic criteria: the ratio (R) of
Bm2+Bm29 to early Bm5+Bm5 is >5 when denoted ‘‘R+’’, and ,5 when denoted ‘‘R2’’.
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in a multicentre prospective study?
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